Assembly Biosciences Inc represents values of innovation, collaboration, and patient-centricity. With a vision to redefine the treatment of infectious diseases, the company is driven by its corporate philosophy of improving the lives of patients through groundbreaking research and scientific advancements. Assembly Biosciences Inc prioritizes developing novel therapeutics that target and eliminate viral diseases, leveraging its proprietary platform technology. By combining expertise in biology, chemistry, and virology, the company aims to address significant unmet medical needs. Assembly Biosciences Inc's commitment to scientific discovery and delivering positive patient outcomes shapes its corporate philosophy, guiding its efforts to revolutionize infectious disease treatments.

Assembly Biosciences Inc is primarily present in the United States.

Assembly Biosciences Inc has achieved several significant milestones. The company successfully completed a Phase 1 clinical trial for its lead candidate, ABI-H0731, in patients with chronic hepatitis B virus (HBV) infection. This milestone demonstrated the safety and tolerability of the drug candidate, bringing hope to the millions suffering from HBV worldwide. Additionally, Assembly Biosciences Inc entered into a collaboration with AbbVie, a global biopharmaceutical company, to develop potential oral therapies for HBV. This partnership provides further validation of Assembly Biosciences Inc's innovative approaches in the field of virology. As the company continues to progress in its research and development efforts, it aims to provide groundbreaking solutions for patients with HBV.

Assembly Biosciences Inc., a leading biotechnology company, has a rich history and background. Established in 2005, this innovative company focuses on developing novel therapeutics to address unmet medical needs in the field of microbiome science. Assembly Biosciences Inc. is dedicated to leveraging its expertise in the human microbiome to create potential treatments for various diseases, including infectious and gastrointestinal disorders. With a strong commitment to research and groundbreaking developments, Assembly Biosciences Inc. has garnered significant recognition within the scientific and investment community. This company continues to drive advancements in microbiome-based therapies, aiming to improve the lives of patients worldwide.

Some of the main competitors of Assembly Biosciences Inc in the market include AbbVie Inc., Gilead Sciences Inc., Johnson & Johnson, Merck & Co. Inc., and Vertex Pharmaceuticals Incorporated.

Assembly Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Assembly Biosciences Inc focuses on the discovery, development, and commercialization of innovative therapies for patients with chronic hepatitis B virus (HBV) infection. The company aims to address the limitations of current treatment options by targeting various aspects of the HBV lifecycle. Assembly Biosciences utilizes its proprietary drug discovery platform, known as HBV Core Protein Allosteric Modulators (CpAMs), to develop potential therapeutics that can impact multiple stages of the HBV lifecycle. By tailoring CpAMs, Assembly Biosciences aims to provide patients with safe and effective treatments that can potentially lead to a functional HBV cure.

Assembly Biosciences KGV ir -1,51.

Assembly Biosciences KUV ir 3,07.

AlleAktien kvalitātes vērtējums Assembly Biosciences ir 4/10.

gaidāmā Assembly Biosciences apgrozījums ir 23,54 milj. USD.

gaidāmā Assembly Biosciences peļņa ir -47,99 milj. USD.

Assembly Biosciences Inc. is a publicly traded company focused on researching, developing, and commercializing new therapies for chronic infectious diseases. The company is headquartered in South San Francisco, California, and also has offices in Durham, North Carolina, and in the UK. Assembly Biosciences aims to improve the lives of patients suffering from life-threatening infectious diseases. Its business model is centered around the development of drugs for chronic liver diseases, particularly hepatitis B. The company has two main divisions: research and development (R&D) and commercial development. The R&D division focuses on discovering and developing new innovative therapies for chronic liver diseases, while the commercial development division aims to market already developed drugs. Assembly Biosciences is specifically focused on developing new drugs for hepatitis B, a chronic viral infection that can damage the liver and sometimes lead to liver cancer. The currently available drugs for hepatitis B are unable to completely eliminate the virus, meaning patients infected with hepatitis B must live with it for life. Assembly Biosciences has developed an innovative concept to combat hepatitis B, with the goal of developing a new class of drugs that can completely eliminate the virus. The company has already achieved promising results in preclinical research and is now working on developing drugs for clinical trials. The commercial development division of Assembly Biosciences is focused on bringing already developed drugs for chronic liver diseases to the market. The company has exclusive global rights to the technology platforms of Arbutus Biopharma and focus, both of which focus on developing drugs for hepatitis B. Through these partnerships, Assembly Biosciences has already acquired technology platforms and expertise in drug development. One example of a product marketed by Assembly Biosciences is VEN 307. VEN 307 is a virologically effective component-independent lipid particle based on the technology platform of Arbutus Biopharma. VEN 307 is intended to help patients with chronic hepatitis B reduce their viral load and improve their liver health. The drug is currently in a phase IIa clinical trial. Overall, Assembly Biosciences has developed a promising business model based on the development of new innovative therapies for chronic liver diseases. With its R&D division and partnerships, the company has already made promising developments that will be tested in clinical trials. The commercial development division aims to bring already developed drugs for hepatitis B to the market, making an important contribution to improving the quality of life for patients with chronic liver diseases.

Assembly Biosciences izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Assembly Biosciences vai uzņēmums nedod dividendes.

Assembly Biosciences ISIN ir US0453961080.

Assembly Biosciences WKN ir A117S1.

Assembly Biosciences simbols ir ASMB.

Pēdējo 12 mēnešu laikā Assembly Biosciences maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Assembly Biosciences plāno maksāt dividendes 0 USD apmērā.

Assembly Biosciences pašreizējā dividendu rentabilitāte ir .

Assembly Biosciences maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Assembly Biosciences pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Assembly Biosciences tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Assembly Biosciences apmērā 0 USD, kas tika izmaksāta 28.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 28.09.2024..

Pēdējās dividendes izmaksa notika 28.09.2024..

Gadā 2023, Assembly Biosciences izmaksāja 0 USD dividendes.

Assembly Biosciences dividendes tiek izmaksātas USD.